Presenters: Lorena Lopez-Gonzalez, G1 Therapeutics, Inc., Research Triangle Park, NC; Michelle Moore, RPh, G1 Therapeutics, Inc., Research Triangle Park, NC
Co-Authors: Jerome Goldschmidt, MD, Blue Ridge Cancer Centers, US Oncology Research, Blacksburg, VA; Alisha Monnette, PhD, MPH, Ontada, Woodlands, TX; Divea Venkatasetty, MPH, Ontada, Woodlands, TX; Ping Shi, PhD, Ontada, Woodlands, TX; Huan Huang, PhD, G1 Therapeutics, Inc., Research Triangle Park, NC; Paul R. Conkling, MD, US Oncology Research, Norfolk, VA
BACKGROUND: Chemotherapy-induced myelosuppression, which leads to the reduced production of multiple cell lineages (white blood cells, red blood cells [RBCs], and/or platelets), is a major dose-limiting adverse event of chemotherapy. A previous study reported that 56.6% of patients with extensive-stage small-cell lung cancer (ES-SCLC) who received chemotherapy and were in the US Oncology Network (Network) had grade ≥3 myelosuppression events in ≥1 lineage and 33% in ≥2 lineages after chemotherapy initiation.1
OBJECTIVE: To evaluate the real-world outcomes of patients with ES-SCLC who received trilaciclib in the community oncology setting.
METHOD: This retrospective study included adult patients with ES-SCLC who initiated trilaciclib during chemotherapy in Network clinics between February 1, 2021, and April 30, 2022. Patients without evidence of receiving chemotherapy treatment or who were in clinical trials were excluded. The outcomes included myelosuppression events (ie, anemia, neutropenia, thrombocytopenia) and supportive care utilization (ie, eligibility for RBC or platelet transfusion, granulocyte colony-stimulating factor [G-CSF] use) occurring between the first trilaciclib administration and 14 days after the last trilaciclib administration during index chemotherapy.
RESULTS: Patients with ES-SCLC (N = 31) received an average of 3.1 cycles (median, 3) of index chemotherapy during the use of trilaciclib and an average of 8.6 administrations (median, 9) of trilaciclib during index chemotherapy. Grade ≥3 myelosuppression events in ≥1 lineage occurred in 35.7% of patients (anemia, 7.1%; neutropenia, 28.6%; thrombocytopenia, 7.1%), and 7.1% of patients had grade ≥3 myelosuppression events in ≥2 lineages. During the index chemotherapy when trilaciclib was used, 9.7% of patients received G-CSF, 3.2% were eligible for RBC transfusions, and none of the patients were eligible for platelet transfusions.
CONCLUSION: Early real-world data in this study suggest that trilaciclib may reduce myelosuppression in patients with ES-SCLC who receive treatment in the community oncology setting. More research is recommended to validate these findings.
Previously presented, in part, at 2022 Precision Oncology Summit, October 2022.
- Goldschmidt J, Monnette A, Shi P, et al. Real-world burden of myelosuppression among patients with extensive-stage small-cell lung cancer treated in the community oncology setting. Poster presented at AMCP Nexus; October 18-21, 2021. Poster C10.